Browsing "Infectious Diseases" by Keyword : SARS-CoV-2
Showing results 6 to 18 of 18
Pub Year | | Title | Author(s) |
2021 | | Effects of early corticosteroid use in patients with severe coronavirus disease 2019 | 김은진 |
2024 | | Harnessing SARS-CoV-2-specific CD8+ T cells to kill target tumor cells for cancer immunotherapy | 김영롱, 정근옥, 허중연 |
2023 | | Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection | 허중연 |
2022 | | Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study | 허중연 |
2023 | | Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | 김은진, 허중연 |
2020 | | Interim Guidelines on Antiviral Therapy for COVID-19 | 허중연 |
2024 | | Longitudinal immune kinetics of COVID-19 booster versus primary series vaccination: Insight into the annual vaccination strategy | 허중연, 현학준 |
2023 | | Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations | 현학준 |
2023 | | Predictive Value of Reactogenicity for Anti-SARS-CoV-2 Antibody Response in mRNA-1273 Recipients: A Multicenter Prospective Cohort Study | 허중연 |
2022 | | Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial | 허중연 |
2022 | | Seek COVER: using a disease proxy to rapidly develop and validate a personalized risk calculator for COVID-19 outcomes in an international network | 박래웅, 최영화 |
2023 | | Six-month longitudinal immune kinetics after mRNA-1273 vaccination: Correlation of peak antibody response with long-term, cross-reactive immunity | 허중연 |
2022 | | Viable SARS-CoV-2 shedding under remdesivir and dexamethasone treatment | 김영롱, 유진세, 허중연 |
1